Business
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the appointment of Chris Chapman as its Chief Commercial Officer. “It is my pleasure to welcome Chris Chapman to the Verrica team as our new Chief Commercial Officer,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer. “Chris has an ex
About this update from Verrica Pharmaceuticals Inc.
[{"type":"image","alt":"Verrica Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Verrica Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":268,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/35B6rwmMy25cs4KMlGMlxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b","width":268,"height":117}},"lazy":false},{"type":"text","content":"WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the appointment of Chris Chapman as its Chief Commercial Officer.","length":312,"tagName":"p"},{"type":"text","content":"“It is my pleasure to welcome Chris Chapman to the Verrica team as our new Chief Commercial Officer,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer. “Chris has an extraordinary track record of successfully commercializing several products in dermatology and other specialties, and has had success in building and leading commercial organizations in dynamic and competitive markets. I am confident that Chris’ commercial acumen will broaden access to YCANTH for molluscum patients and bring critical insights to our global Phase 3 program for common warts as well as the development of VP-315, our novel oncolytic peptide for basal cell carcinoma.”","length":669,"tagName":"p"},{"type":"text","content":"“I am excited to join Verrica at a time when YCANTH is becoming the new standard of care for the millions of children impacted by molluscum contagiosum,” said Mr. Chapman. “YCANTH represents a rare product opportunity based not only on its growth potential in molluscum, but also as a potential future treatment for common warts, an indication impacting millions of additional patients for which there are no FDA-approved therapies. I am also excited by the opportunity for Verrica’s other pipeline candidate, VP-315, which has the potential to become a best-in-class non-surgical immunotherapeutic option for the treatment of basal cell carcinoma. I relish the opportunity to lead and grow the U.S. commercial organization, whil...